Table 1. Patient, tumour and treatments characteristics.

Characteristic		Primary		Recurrence
Patient		(n)	Median (range) / %	(n)	Median (range) / %
Age (years)			54(23-83)		60(30-89)
Time to recurrence (months)					41
pT size cm			4.3 (0.3-19)		6.5(0.5-22)
Grade	1	1	2.9	3	10.7
	2	13	38.2	5	17.8
	3	20	58.8	20	71.4
	Unknown	15		30
Estrogen R	Positive	24	53	21	63.6
	Negative	21	46	12	36.4
	Unknown	4		16
Progesterone R	Positive	13	34	12	46.1
	Negative	25	65	14	53.8
	Unknown	11		23
Her2 Status	Positive	8	26	1	3.3
	Negative	22	73	29	96.6
	Unknown	19		19
LVI	Positive	17	60	5	45.4
	Negative	11	39	6	54.5
	Unknown	21		38
LN	Positive	26	61	12	66.6
	Negative	16	38	6	33.3
	Unknown	7		31
Skin involved	Positive	8	25	15	53.5
	Negative	24	75	13	46.4
	Unknown	17		21
Margin	Macro +	5	17	32	72.7
	Micro +	4	14	3	6.8
	Negative	19	67	9	20.4
	Unknown	21		5
Treatment
Surgery	Mastectomy	22	46	11	22.4
	Lumpectomy	24	50	7	14.2
	None	3	4	31	63.2
Axilar Dissection	Yes	15	37	5	11.6
	No	26	63	38	88.3
	Unknown	8		6
SLN Dissection	Yes	21	53	3	6.8
	No	19	47	41	93.1
	Unknown	9		5
Hormonal Treat.*	Yes	23	58	20	57.1
	No	17	42	15	42.8
	Unknown	7		12
Chemotherapy*	Yes	34	68	34	79.0
	No	7	32	8	18.6
	Unknown	6		5
Radiotherapy	Breast/Chest Wall	41		48
	Partial breast	0		8
	Axila/SCV	24		16
	Dose (Gy)		50.0		50.0
	Std fx	35	50.0	24	50.0
	Hyperfx	3	65.0	6	65.0
	Hypofx	9	42.5	18	42.5
	Unkown	2		1
	Boost	21		17
	WBRT Dose EQD2 α/β=10	48.3		96.7
	WBRT Dose EQD2 α/β=3	48.7		99.8
	Tu Cavity Dose EQD2 α/β= 10	55.3		105.9
	Tu Cavity Dose EqD2 α/β =3	55.8		109.1

SCV: Supraclavicular, LN: lymphnode, LVI: lymphvascular invasion, SLN: Sentinel lymphnode, WBRT: whole breast radiation therapy

^*n=47 (2 patients had bilateral treatment)